Design, synthesis and molecular modeling of biquinoline-pyridine hybrids as a new class of potential EGFR and HER-2 kinase inhibitors

A new series of biquinoline-pyridine hybrids were designed and synthesized by a base-catalyzed cyclocondensation through one-pot multicomponent reaction. All compounds were tested for in vitro Anticancer activities against two Cancer cell lines A549 (adenocarcinomic human alveolar basal epithelial) and Hep G2 (liver Cancer). Enzyme inhibitory activities of all compounds were carried out against EGFR and HER-2 kinase. Of the compounds studied, majority of the compounds showed effective Anticancer activity against used Cancer cell lines. Compound 9i (IC50=0.09 μM) against EGFR and (IC50=0.2 μM) against HER-2 kinase displayed the most potent inhibitory activity as compared to Other member of the series. In the molecular modelling study, compound 9i was bound in to the active pocket of EGFR with four hydrogen bonds and two π-cation interactions having minimum binding energy ΔGb=-54.4 kcal/mol.

Anticancer activity; Molecular modeling; One-pot reaction; Pyridine; Tetrazolo[1,5-a]quinoline-4-carbaldehyde biquinoline.